IGF2: The Achilles' heel of p53-deficiency?

EMBO Molecular Medicine

Volumn 4, Issue 8, 2012, Pages 688-690

  Clermont, Frederic ^a   Nittner, David ^a   Marine, Jean Christophe ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cancer; IGF2; Mouse genetics; P53; Synthetic lethality

Indexed keywords

PROTEIN P53; SOMATOMEDIN B; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ARTICLE; CARCINOGENESIS; DISEASE ASSOCIATION; GENE DELETION; HETEROZYGOSITY; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE, KNOCKOUT; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864809342     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201509     Document Type: Article

References (12)

1. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5: 931-936
2. Avnet S, Perut F, Salerno M, Sciacca L, Baldini N (2012) Insulin receptor isoforms are differently expressed during human osteoblastogenesis. Differentiation 83: 242-248
3. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873
4. Christofori G, Naik P, Hanahan D (1994) A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369(6479), 414-418
5. Christofori G, Naik P, Hanahan D (1995) Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis. Nat Genet 10: 196-201
6. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
7. Gabory A, Ripoche MA, Le Digarcher A, Watrin F, Ziyyat A, Forne T, Jammes H, Ainscough JF, Surani MA, Journot L, et al (2009) H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development 136: 3413-3421
8. Haley VL, Barnes DJ, Sandovici I, Constancia M, Graham CF, Pezzella F, Bühnemann C, Carter EJ, Hassan AB (2012) Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes. EMBO Mol Med. DOI: 10.1002/emmm.201101105
9. Ho L, Stojanovski A, Whetstone H, Wei QX, Mau E, Wunder JS, Alman B (2009) Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16: 126-136
10. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4 1-7
11. Kaelin WG, Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698
12. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331